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5 metastases of melanoma is similar to that found in peripheral sites (Capper et al., 2011) . Given the prevalence of BRAF V600E mutations in a large number of melanomas, BRAF has been an attractive treatment target for melanoma patients with V600E
mutation, and as such many small-molecule inhibitors of BRAF have been developed.
Vemurafenib (previously known as PLX4032) is a small molecule BRAF V600E inhibitor that was developed using a structure-guided drug discovery approach (Tsai et al., 2008) . It was approved by U.S. A major factor contributing to the rapid and near 100% mortality in melanoma patients with brain metastases has been the presumed limited permeability of chemotherapeutics across the blood-brain barrier (BBB). The BBB is a highly evolved vasculature structure which limits most molecules from distributing into the brain from the blood compartment. Anatomically, the vasculature of the BBB is unique in that it is comprised of endothelial cells, that are circumferentially sealed together by tightjunction protein complexes, that form the lumen of the vessel. Further, active efflux
6 transporters that are present on the luminal side of capillary endothelium efficiently pump out the drugs from the brain to the blood circulation. Adenosine triphosphatebinding cassette proteins (ABC) such as P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) are major members of the efflux transporters present on the luminal membrane of the brain capillary endothelial cells (Schinkel and Jonker, 2003) .
Studies have shown that many therapeutic agents are substrates of these transporters and as a result have very limited brain distribution (Loscher and Potschka, 2005) .
Vemurafenib can be considered a "sea-change" in the treatment of melanoma patients. However, important questions still remain regarding resistance and effective delivery to all sites of melanoma metastases, particularly in brain. In this regard, there is a paucity of data regarding the delivery of anti-melanoma agents to brain metastases.
Given the remarkable activity of the novel targeted BRAF V600E inhibitors in peripheral disease, it becomes critical to examine the mechanisms that may limit their delivery to brain metastases. Whether vemurafenib can cross the BBB to achieve therapeutic levels in the CNS remains unknown. This has motivated us to examine the interaction of vemurafenib with the two main BBB efflux transporters, namely P-gp and BCRP.
Herein, using in vitro models, we show that vemurafenib is an avid substrate for both Pgp and BCRP. In vivo studies using genetic knockout mice indicate both transporters play a significant role in limiting the CNS distribution of vemurafenib.
8
In vitro accumulation studies: The intracellular accumulation of vemurafenib was performed in 12-well polystyrene plates (Corning Inc. Corning, NY) as described previously (Agarwal et al., 2010; Agarwal et al., 2011) . Briefly, cells were seeded at a density of 2 x 10 5 cells and were grown until the cells were ~80% confluent. On the day of experiment the culture media was aspirated and the cells were washed two times with cell assay buffer (122 mM NaCl, 25 mM NaHCO 3 , 10 mM glucose, 10 mM HEPES, 3 mM KCl, 2.5 mM MgSO 4 , 1.8 mM CaCl 2 , and 0.4 mM K 2 HPO 4 ). Then the cells were preincubated with assay buffer for 30 min, after which the buffer was aspirated and the experiment was initiated by adding 1 mL of vemurafenib (2 µM) to each well and further incubated for 60 min. The assay plates were incubated at 37º C on an orbital shaker (60 rpm) for the entire duration of the experiment. After the incubation period, the drug solution was aspirated and the cells were washed twice with ice cold PBS. Then the cells were lysed by adding 500 µL of 1% Triton X to each well. A 400 µL of solubilized cell fraction was sampled from each well and the concentration of vemurafenib was determined using LC-MS/MS as described below.
Directional transport across MDKCII monolayers:
The bidirectional flux studies were performed using 6-well Transwell ® plates (Cornings Inc. Lowell, MA). The cells were seeded at a density of 2 x10 5 cells per well and the media was changed every other day until confluent monolayers were formed. On the day of experiment, the culture medium was aspirated and the cells were washed twice with assay buffer and after 30 min Transwell ® plates were incubated at 37 ºC on an orbital shaker for the duration of experiment except for the brief sampling times. When an inhibitor was used, the inhibitor was present in the both compartments during the pre and post incubation period.
The apparent permeability (P app ) for the directional transport was calculated as previously described (Agarwal et al., 2011) . The permeabilities were calculated using the following equation
Where, (dQ/dt) is the slope obtained from the initial linear range from the amount transported versus time plot, A is the area of the Transwell ® membrane, and C 0 is the initial donor concentration. The efflux ratio and corrected efflux ratio were calculated using eqs. 2 and 3, respectively,
where A→B represents permeability in apical to basolateral and B→A represents permeability in basolateral to apical direction.
This article has not been copyedited and formatted. The final version may differ from this version. received an oral dose of 25 mg/kg and blood and brain samples were collected 1 and 4 hr post dose. At the end of the desired time point, the animals were euthanized using a CO 2 chamber. Blood was collected via cardiac puncture and collected in heparinized tubes. Plasma was obtained by centrifuging the blood at 7500 rpm for 10 min. Brains were rapidly removed from the skull, rinsed with ice cold PBS followed by a flash freeze in liquid nitrogen. Brain and plasma samples were stored at -80º C until further analysis.
In the i.v. dosing study, wild type and Mdr1a/b -/-Bcrp1 -/-mice were administered vemurafenib via the tail vein at a dose of 2.5 mg/kg. Blood and brain samples were processed after 5, 30, 90, 180, 300, and 480 minutes (n=4 for each time point) as mentioned above.
Steady state brain distribution of vemurafenib:
To determine the steady state brain and plasma concentrations of vemurafenib, Alzet osmotic mini pumps (Durect Corporation, Cupertino, CA) were loaded with vemurafenib (25 mg/mL dissolved in DMSO) to be released for 48 hrs at a rate of 1µL/hr. After vemurafenib loading, mini pumps were primed overnight in sterile saline at 37 º C. Pumps were implanted in the peritoneal cavity of wild type, Mdr1a/b -/-, Bcrp1 -/-, and Mdr1a/b -/-Bcrp1 -/-mice as previously described (Agarwal et al., 2010; Agarwal et al., 2011) . Briefly, mice were anesthetized using isofluorane and the abdominal cavity was shaved. A small midline incision was made in the lower abdomen under the rib cage. Then a small incision was made directly in the peritoneal membrane and the primed pump was inserted in the cavity. The incision was sutured and the skin was closed using surgical clips. The animals were allowed to recover on a heating pad and, once recovered, moved to their was 4.2 and 2.9 min, respectively. The assay was sensitive and linear over a range of 1.2 ng/mL to 1.2 µg/mL, with the coefficient of variation being less than 15% over the entire range.
Pharmacokinetic Calculations: Pharmacokinetic parameters and metrics were calculated by noncompartmental methods using Phoenix WinNonlin (Version 6.1) (Pharsight, Mountain View, CA). The area under the concentration time curve in both plasma and brain was calculated using the trapezoidal rule, and the area under the curve was determined up to the last measured time point (AUC 0-tlast ). AUC 0-tlast was used in determining brain to plasma distribution ratio. The area under the curve from time zero to infinity was also determined and the area extrapolated was less than 20% of the total area under the concentration curve. The terminal rate constants were determined using all the data points in the brain and the last three data points in the (GraphPad Prism 5.01 software, San Diego, CA, USA). .
RESULTS:

Intracellular accumulation of vemurafenib:
The intracellular accumulation of vemurafenib was studied in MDCKII WT and P-gp or Bcrp overexpressing cell lines.
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(WT: 100.0 ± 2.6; MDR1: 73.6 ± 5.5, p<0.05), and the difference in accumulation was abolished (Fig. 1B) when a specific P-gp inhibitor LY335979 was added (MDR1: 73.6 ± 5.5; MDR1 with LY: 110.8 ± 2.9). The aggregate of these data indicates that vemurafenib is a substrate for both P-gp and Bcrp in vitro.
Competition assays:
The in vitro competition assays for vemurafenib were performed in MDCKII cells using vinblastine and prazosin as P-gp and Bcrp prototype probe Fig. 2A) . Similarly, at 25 µM of vemurafenib, the fold increase in vinblastine accumulation was no different than the effect seen with the potent P-gp inhibitor LY335959 (Fig. 2B) in MDCKII-MDR1 cells.
These data suggest that vemurafenib may share the same binding sites on the transporter proteins as these prototypical probe substrates.
Bidirectional flux across MDCKII monolayers:
The in vitro transport (apical to basolateral, A to B; and basolateral to apical, B to A) of vemurafenib was studied in MDCKII wild type, and P-gp or Bcrp overexpressing cell lines. Fig. 3A and 3B
demonstrate the transport of vemurafenib in the A to B and B to A direction in Bcrp1 and corresponding wild-type cell monolayers. In the wild type cells, there was minimal transport (less than 2.3% in 1.5 hrs) of vemurafenib in either direction (Fig. 3A) . In case of the MDCKII-Bcrp1 cells, the permeability of vemurafenib in the B to A direction was significantly higher than the permeability in the A to B direction [A to B: (0.02 ± 0.003 ×
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1 6 10 -6 cm/s); B to A: (9.9 ± 6.8 × 10 -6 cm/s); p <0.05; Fig. 3C ]. The addition of 0.2 µM Ko143, a specific Bcrp inhibitor, resulted in partial inhibition of Bcrp mediated vemurafenib transport in these cells (Fig. 3C) .
The transport of vemurafenib in the A to B and B to A direction in MDR1 and corresponding wild-type cell monolayers is depicted in Fig. 3D and 3E Table 1 .
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In a separate study, the brain distribution of vemurafenib in Mdr1a/b -/-Bcrp1 -/-mice was examined after an i.v. dose of 2.5 mg/kg. As shown in Fig. 5B , the brain concentrations of vemurafenib in Mdr1a/b -/-Bcrp1 -/-mice were significantly higher than in wild type mice. The plasma concentrations were not different between the two types of mice (Fig. 5A) . The brain to plasma (B/P) ratio of vemurafenib in wild-type mice was ~0.4%, significantly lower than the B/P ratio in Mdr1a/b -/-Bcrp1 -/-mice (Fig. 5C ). Vemurafenib was delivered at a constant infusion for 48 hrs at a rate of 25µg/hr, and the brain and plasma concentrations were determined thereafter. Panel A shows the steady state brain and plasma concentrations of vemurafenib, and panel B shows the B/P ratio in all four type mice. The B/P ratios were not significantly different in single knockout mice when compared to wild type mice. However the B/P ratio in triple knockout mice was significantly higher than the wild type mice, indicating the "cooperative" role of P-gp and Bcrp at the blood-brain barrier. A *, and *** indicates a p value of <0.01 and <0.0001 respectively. Data are mean ± SD; n=3-4 for all data points.
Brain distribution of vemurafenib after oral administration:
This article has not been copyedited and formatted. The final version may differ from this version. Plasma and brain pharmacokinetic parameters were analyzed using non compartmental analysis after an i.v. dose of 2.5 mg/kg in FVB wild-type mice. The AUC brain to AUC plasma ratio of 0.004 indicates the severely restricted brain distribution of vemurafenib.
